Should I buy or sell Royalty Pharma stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RPRX shares. View RPRX analyst ratings or view top-rated stocks .

What is Royalty Pharma's stock price target for 2024?

4 Wall Street analysts have issued 12 month price targets for Royalty Pharma's shares. Their RPRX share price targets range from $38.00 to $57.00. On average, they predict the company's stock price to reach $46.75 in the next twelve months. This suggests a possible upside of 69.3% from the stock's current price. View analysts price targets for RPRX or view top-rated stocks among Wall Street analysts .

How have RPRX shares performed in 2024?

Royalty Pharma's stock was trading at $28.09 at the beginning of 2024. Since then, RPRX shares have decreased by 1.7% and is now trading at $27.61. View the best growth stocks for 2024 here .

When is Royalty Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RPRX earnings forecast .

How were Royalty Pharma's earnings last quarter?

Royalty Pharma plc (NASDAQ:RPRX) issued its quarterly earnings data on Thursday, February, 15th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.12. The biopharmaceutical company had revenue of $736 million for the quarter, compared to analysts' expectations of $702.90 million. Royalty Pharma had a net margin of 48.22% and a trailing twelve-month return on equity of 26.93%.

How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma?

Royalty Pharma declared a quarterly dividend on Friday, January 19th. Shareholders of record on Friday, February 16th will be paid a dividend of $0.21 per share on Friday, March 15th. This represents a $0.84 annualized dividend and a yield of 3.04%. The ex-dividend date is Thursday, February 15th. This is a positive change from the stock's previous quarterly dividend of $0.20. Read our dividend analysis for RPRX .

Is Royalty Pharma a good dividend stock?

Royalty Pharma (NASDAQ:RPRX) pays an annual dividend of $0.84 per share and currently has a dividend yield of 2.97%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RPRX will have a dividend payout ratio of 19.44% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for RPRX .

What ETFs hold Royalty Pharma's stock?

ETFs with the largest weight of Royalty Pharma (NASDAQ:RPRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , iShares U.S. Pharmaceuticals ETF (IHE) , Formidable ETF (FORH) , Simplify Health Care ETF (PINK) , Fidelity Disruptive Medicine ETF (FMED) , Invesco Nasdaq Biotechnology ETF (IBBQ) and Invesco NASDAQ Next Gen 100 ETF (QQQJ) .

What other stocks do shareholders of Royalty Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR) , Bausch Health Companies (BHC) , NVIDIA (NVDA) , (RLYP) (RLYP) , Aeterna Zentaris (AEZS) , Advanced Micro Devices (AMD) , Netflix (NFLX) , QUALCOMM (QCOM) , Salesforce (CRM) and Twilio (TWLO) .

When did Royalty Pharma IPO?

Royalty Pharma (RPRX) raised $1.9 billion in an initial public offering on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank served as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers.

Who are Royalty Pharma's major shareholders?

Royalty Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.12%), Overbrook Management Corp (0.04%), Alaska Permanent Fund Corp (0.01%), Financiere des Professionnels Fonds d investissement inc. (0.01%), Ballentine Partners LLC (0.00%) and First Hawaiian Bank (0.00%). Insiders that own company stock include 1978 Sicaf Sif SA - Gg St Gg, 1978 Sicaf Sif SA Gg, Avara Management Ltd, George W Lloyd , Henry A Fernandez , James F Reddoch, James F Reddoch , Mario Germano Giuliani , Marshall Urist , Pablo G Legorreta , Rory B Riggs , Sanjay Kumar Singh , Scientific Corp Boston and Terrance P Coyne . View institutional ownership trends .

How do I buy shares of Royalty Pharma?

Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RPRX

Royalty Pharma (RPRX) Stock Price, News & Analysis

→ This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad)

Free RPRX Stock Alerts

$27.61

+0.15 (+0.55%)

(As of 04/17/2024 ET)

Compare

Today's Range: $27.43
▼
$27.78
50-Day Range: $27.46
▼
$31.33
52-Week Range: $25.92
▼
$36.67

Volume: 2.33 million shs
Average Volume: 2.67 million shs
Market Capitalization: $16.50 billion

P/E Ratio: 14.61
Dividend Yield: 3.04%
Price Target: $46.75

Get Royalty Pharma alerts:

Royalty Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 69.3% Upside
$46.75 Price Target
Short Interest: Healthy
3.27% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: -2.25
Upright™ Environmental Score
News Sentiment: 0.31
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 9.37%
From $3.95 to $4.32 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.93 out of 5 stars

Finance Sector

36th out of 831 stocks

Pharmaceutical Preparations Industry

7th out of 406 stocks

3.5

Analyst's Opinion

Consensus Rating
Royalty Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Royalty Pharma has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.27% of the float of Royalty Pharma has been sold short.
Short Interest Ratio / Days to Cover
Royalty Pharma has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Royalty Pharma has recently decreased by 2.06%, indicating that investor sentiment is improving.

2.5

Dividend Strength

Dividend Yield
Royalty Pharma pays a meaningful dividend of 2.97%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Royalty Pharma has only been increasing its dividend for 4 years.
Dividend Coverage
The dividend payout ratio of Royalty Pharma is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Royalty Pharma will have a dividend payout ratio of 19.44% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Royalty Pharma has received a 47.64% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Rotavirus vaccine", "HIV medication", "Breast cancer medication", "Prostate cancer medication", "Rheumatoid arthritis medication", and "Multiple myeloma medication" products. See details.
Environmental Sustainability
The Environmental Impact score for Royalty Pharma is -2.25.

2.4

News and Social Media Coverage

News Sentiment
Royalty Pharma has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Finance companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Royalty Pharma this week, compared to 4 articles on an average week.
Search Interest
Only 19 people have searched for RPRX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
MarketBeat Follows
21 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 5% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Royalty Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
18.72% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.8

Earnings and Valuation

Earnings Growth
Earnings for Royalty Pharma are expected to grow by 9.37% in the coming year, from $3.95 to $4.32 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Royalty Pharma is 14.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.66.
Price to Earnings Ratio vs. Sector
The P/E ratio of Royalty Pharma is 14.61, which means that it is trading at a less expensive P/E ratio than the Finance sector average P/E ratio of about 56.90.
Price to Earnings Growth Ratio
Royalty Pharma has a PEG Ratio of 0.80. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Royalty Pharma has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Royalty Pharma Stock (NASDAQ:RPRX)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

RPRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RPRX Stock News Headlines

April 17, 2024 | seekingalpha.com

Royalty Pharma declares $0.21 dividend

April 17, 2024 | finance.yahoo.com

Royalty Pharma Declares Second Quarter 2024 Dividend

April 17, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 17, 2024 | globenewswire.com

Royalty Pharma Declares Second Quarter 2024 Dividend

April 15, 2024 | americanbankingnews.com

Royalty Pharma plc (NASDAQ:RPRX) Receives $46.75 Average PT from Brokerages

April 14, 2024 | nasdaq.com

Relative Strength Alert For Royalty Pharma

April 14, 2024 | americanbankingnews.com

Royalty Pharma (NASDAQ:RPRX) Price Target Cut to $38.00

April 11, 2024 | investorplace.com

3 Pharma Stocks to Sell in April Before They Crash & Burn

April 17, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 11, 2024 | americanbankingnews.com

Royalty Pharma (NASDAQ:RPRX) Rating Increased to Buy at StockNews.com

April 9, 2024 | investorplace.com

Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You've Never Heard Of)

April 9, 2024 | investorplace.com

April's Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio

April 5, 2024 | nasdaq.com

January 2025 Options Now Available For Royalty Pharma (RPRX)

March 30, 2024 | finance.yahoo.com

Royalty Pharma plc's (NASDAQ:RPRX) Stock Has Shown A Decent Performance: Have Financials A Role To Play?

March 27, 2024 | investorplace.com

The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio

March 16, 2024 | ca.finance.yahoo.com

RPRX Dec 2024 17.500 call

March 16, 2024 | ca.finance.yahoo.com

RPRX Oct 2024 40.000 put

March 11, 2024 | msn.com

FDA rejects Viatris/Mapi long-acting version of Teva's Copaxone

March 7, 2024 | nasdaq.com

Notable Two Hundred Day Moving Average Cross - RPRX

February 28, 2024 | finance.yahoo.com

Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference

February 28, 2024 | globenewswire.com

Royalty Pharma to Present at TD Cowen's 44th Annual Health Care Conference

February 19, 2024 | uk.news.yahoo.com

Entertainment firm director hauled before courts for breaking rules

February 18, 2024 | finance.yahoo.com

Analysts Have Made A Financial Statement On Royalty Pharma plc's (NASDAQ:RPRX) Yearly Report

February 17, 2024 | finance.yahoo.com

Royalty Pharma Full Year 2023 Earnings: EPS: US$2.54 (vs US$0.098 in FY 2022)

February 16, 2024 | markets.businessinsider.com

Goldman Sachs Reaffirms Their Buy Rating on Royalty Pharma (RPRX)

February 16, 2024 | msn.com

Royalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

February 16, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Royalty Pharma on Strong Financials and Growth Prospects

See More Headlines

Receive RPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Ex-Dividend for 3/15 Dividend: 2/15/2024
Dividend Payable: 3/15/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Finance
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:RPRX
CUSIP: 76028H20
CIK: 897075
Web: www.royaltypharma.com
Phone: 212-883-0200
Fax: N/A
Employees: 51
Year Founded: 1996

Price Target and Rating

Average Stock Price Target: $46.75
High Stock Price Target: $57.00
Low Stock Price Target: $38.00
Potential Upside/Downside: +69.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.89
Trailing P/E Ratio: 14.64
Forward P/E Ratio: 7.01
P/E Growth: 0.8
Net Income: $1.13 billion
Net Margins: 48.22%
Pretax Margin: 72.20%
Return on Equity: 26.93%
Return on Assets: 15.93%

Debt

Debt-to-Equity Ratio: 0.61
Current Ratio: 7.90
Quick Ratio: 7.90

Sales & Book Value

Annual Sales: $2.36 billion
Price / Sales: 7.02
Cash Flow: $4.47 per share
Price / Cash Flow: 6.19
Book Value: $16.88 per share
Price / Book: 1.64

Miscellaneous

Outstanding Shares: 597,430,000
Free Float: 485,595,000
Market Cap: $16.53 billion
Optionable: Optionable
Beta: 0.45

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Pablo Gerardo Legorreta (Age 59)
Founder, Chairman of the Board & CEO
Mr. Terrance P. Coyne
Executive VP & CFO
Mr. George Wingate Lloyd (Age 65)
Executive VP of Investments & Chief Legal Officer
Comp: $4.35M
Mr. Christopher Hite (Age 57)
Vice Chairman & Executive VP
Comp: $4.35M
Dr. Marshall Urist M.D.
Ph.D., Executive VP and Head of Research & Investments
Mr. Arthur R. McGivern J.D.
Executive Vice President of Investments & General Counsel
Mr. Ashwin Pai M.D.
Executive Vice President of Investments
Ms. Kristin Stafford (Age 41)
Senior VP & Chief Accounting Officer
Mr. Eric Schneider
Senior VP & Chief Technology Officer
Dr. James Folmar Reddoch Ph.D. (Age 54)
Executive VP of Investments & Chief Scientific Officer
Comp: $3.4M

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Royalty Pharma Stock? RPRX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Royalty Pharma plc:

Royalty Pharma stock has shown positive price performance, with a 52-week high of $36.74.
Royalty Pharma has a strong market cap of $17.44 billion, indicating stability and potential growth.
The company has a low price-to-earnings-growth ratio of 0.83, suggesting it may be undervalued compared to its growth prospects.
Royalty Pharma collaborates with various entities in the biopharmaceutical industry, diversifying its revenue streams and reducing risk.
Institutional investors own a significant portion (54.35%) of Royalty Pharma's stock, indicating confidence in the company's future.

Cons

Investors should be bearish about investing in Royalty Pharma plc for these reasons:

The stock has a beta of 0.45, indicating lower volatility compared to the market, potentially limiting short-term gains.
Royalty Pharma's debt-to-equity ratio of 0.61 may raise concerns about its financial leverage and ability to manage debt.
The company's 50-day moving average price of $29.83 is slightly below the current stock price, suggesting a possible short-term downtrend.
Royalty Pharma's quick ratio of 7.90 may indicate challenges in quickly converting assets into cash if needed.
While Royalty Pharma has collaborations, the competitive nature of the biopharmaceutical industry could pose risks to its revenue and market position.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Royalty Pharma pros and cons to contact@marketbeat.com.

RPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Royalty Pharma stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RPRX shares.
View RPRX analyst ratings or view top-rated stocks.
What is Royalty Pharma's stock price target for 2024?: 4 Wall Street analysts have issued 12 month price targets for Royalty Pharma's shares. Their RPRX share price targets range from $38.00 to $57.00. On average, they predict the company's stock price to reach $46.75 in the next twelve months. This suggests a possible upside of 69.3% from the stock's current price.
View analysts price targets for RPRX or view top-rated stocks among Wall Street analysts.
How have RPRX shares performed in 2024?: Royalty Pharma's stock was trading at $28.09 at the beginning of 2024. Since then, RPRX shares have decreased by 1.7% and is now trading at $27.61.
View the best growth stocks for 2024 here.
When is Royalty Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RPRX earnings forecast.
How were Royalty Pharma's earnings last quarter?: Royalty Pharma plc (NASDAQ:RPRX) issued its quarterly earnings data on Thursday, February, 15th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.12. The biopharmaceutical company had revenue of $736 million for the quarter, compared to analysts' expectations of $702.90 million. Royalty Pharma had a net margin of 48.22% and a trailing twelve-month return on equity of 26.93%.
How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma?: Royalty Pharma declared a quarterly dividend on Friday, January 19th. Shareholders of record on Friday, February 16th will be paid a dividend of $0.21 per share on Friday, March 15th. This represents a $0.84 annualized dividend and a yield of 3.04%. The ex-dividend date is Thursday, February 15th. This is a positive change from the stock's previous quarterly dividend of $0.20.
Read our dividend analysis for RPRX.

Is Royalty Pharma a good dividend stock?: Royalty Pharma (NASDAQ:RPRX) pays an annual dividend of $0.84 per share and currently has a dividend yield of 2.97%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RPRX will have a dividend payout ratio of 19.44% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RPRX.
What ETFs hold Royalty Pharma's stock?: ETFs with the largest weight of Royalty Pharma (NASDAQ:RPRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Formidable ETF (FORH), Simplify Health Care ETF (PINK), Fidelity Disruptive Medicine ETF (FMED), Invesco Nasdaq Biotechnology ETF (IBBQ) and Invesco NASDAQ Next Gen 100 ETF (QQQJ).
What other stocks do shareholders of Royalty Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), Salesforce (CRM) and Twilio (TWLO).
When did Royalty Pharma IPO?: Royalty Pharma (RPRX) raised $1.9 billion in an initial public offering on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank served as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers.
Who are Royalty Pharma's major shareholders?: Royalty Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.12%), Overbrook Management Corp (0.04%), Alaska Permanent Fund Corp (0.01%), Financiere des Professionnels Fonds d investissement inc. (0.01%), Ballentine Partners LLC (0.00%) and First Hawaiian Bank (0.00%). Insiders that own company stock include 1978 Sicaf Sif SA - Gg St Gg, 1978 Sicaf Sif SA Gg, Avara Management Ltd, George W Lloyd, Henry A Fernandez, James F Reddoch, James F Reddoch, Mario Germano Giuliani, Marshall Urist, Pablo G Legorreta, Rory B Riggs, Sanjay Kumar Singh, Scientific Corp Boston and Terrance P Coyne.
View institutional ownership trends.
How do I buy shares of Royalty Pharma?: Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RPRX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial